NASDAQ:SNTS - Santarus Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$18,500.00 0.00 (0.00 %)
(As of 11/21/2018 07:17 AM ET)
Previous Close$18,500.00
Today's Range$18,500.00 - $18,500.00
52-Week RangeN/A
Volume1,894 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Santarus, Inc. (Santarus) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by physician specialists. As of December 31, 2012, the Company's marketed and approved products included Uceris (budesonide), Zegerid (omeprazole/sodium bicarbonate), Glumetza (metformin hydrochloride extended release tablets), Cycloset (bromocriptine mesylate) tablets and Fenoglide (fenofibrate) tablets. As of December 31, 2012, the Company's investigational drugs included Ruconest (recombinant human C1 esterase inhibitor), Rifamycin SV MMX, and SAN-300 (anti-VLA-1 antibody). In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc.

Receive SNTS News and Ratings via Email

Sign-up to receive the latest news and ratings for SNTS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
Current SymbolNASDAQ:SNTS
Previous Symbol
CUSIP80281730
Phone+1-858-3145700

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable

Santarus (NASDAQ:SNTS) Frequently Asked Questions

What is Santarus' stock symbol?

Santarus trades on the NASDAQ under the ticker symbol "SNTS."

Has Santarus been receiving favorable news coverage?

Media headlines about SNTS stock have trended somewhat negative on Wednesday, according to InfoTrie. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Santarus earned a news impact score of -1.0 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days.

How do I buy shares of Santarus?

Shares of SNTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Santarus' stock price today?

One share of SNTS stock can currently be purchased for approximately $18,500.00.

What is Santarus' official website?

The official website for Santarus is http://www.santarus.com.

How can I contact Santarus?

Santarus' mailing address is 3611 Valley Centre Dr Ste 400, SAN DIEGO, CA 92130-3331, United States. The biopharmaceutical company can be reached via phone at +1-858-3145700.


MarketBeat Community Rating for Santarus (NASDAQ SNTS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  111 (Vote Outperform)
Underperform Votes:  96 (Vote Underperform)
Total Votes:  207
MarketBeat's community ratings are surveys of what our community members think about Santarus and other stocks. Vote "Outperform" if you believe SNTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel